Effects of iron overload on chronic metabolic diseases

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 6, 2014, Pages 513-526

  Fernández Real, José Manuel ^a,b   Manco, Melania ^c  

^a GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; FERRITIN; HEPCIDIN; INSULIN; IRON; TRANSFERRIN;

ADIPOSE TISSUE; ATHEROSCLEROSIS; BLOOD DONOR; CARDIOVASCULAR EFFECT; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; GLUCOSE METABOLISM; HUMAN; IRON BALANCE; IRON DEPLETION; IRON OVERLOAD; LIPID METABOLISM; METABOLIC DISORDER; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NOTE; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PATIENT IDENTIFICATION; PHLEBOTOMY; PRIORITY JOURNAL; SIDEROSIS; SKELETAL MUSCLE; CHRONIC DISEASE; LIVER; LIVER DISEASE; METABOLISM;

CHRONIC DISEASE; FERRITINS; HUMANS; IRON; IRON OVERLOAD; LIVER; LIVER DISEASES; SIDEROSIS; TRANSFERRIN;

EID: 84901603732     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70174-8     Document Type: Note

References (115)

1. Finch C Regulators of iron balance in humans. Blood 1994, 84:1697-1702.
2. Carpenter CE, Mahoney AW Contributions of heme and nonheme iron to human nutrition. Crit Rev Food Sci Nutr 1992, 31:333-367.
3. Monsen ER Iron nutrition and absorption: dietary factors which impact iron bioavailability. J Am Diet Assoc 1988, 88:786-790.
4. Hentze MW, Muckenthaler MU, Galy B, Camaschella C Two to tango: regulation of mammalian iron metabolism. Cell 2010, 142:24-38.
5. Davis RJ, Corvera S, Czech MP Insulin stimulates cellular iron uptake and causes the redistribution of intracellular transferrin receptors to the plasma membrane. J Biol Chem 1986, 261:8708-8711.
6. Pietrangelo A Hemochromatosis: an endocrine liver disease. Hepatology 2007, 46:1291-1301.
7. Martinelli N, Traglia M, Campostrini N, et al. Increased serum hepcidin levels in subjects with the metabolic syndrome: a population study. PLoS One 2012, 7:e48250.
8. Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999, 117:1155-1163.
9. Dongiovanni P, Fracanzani AL, Fargion S, Valenti L Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 2011, 55:920-932.
10. Dmochowski K, Finegood DT, Francombe W, Tyler B, Zinman B Factors determining glucose tolerance in patients with thalassemia major. J Clin Endocrinol Metab 1993, 77:478-483.
11. McClain DA, Abraham D, Rogers J, et al. High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia 2006, 49:1661-1669.
12. Noetzli LJ, Mittelman SD, Watanabe RM, Coates TD, Wood JC Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol 2012, 87:155-160.
13. Merkel PA, Simonson DC, Amiel SA, et al. Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N Engl J Med 1988, 318:809-814.
14. Manco M Metabolic syndrome in childhood from impaired carbohydrate metabolism to nonalcoholic fatty liver disease. J Am Coll Nutr 2011, 30:295-303.
15. Simcox JA, McClain DA Iron and diabetes risk. Cell Metab 2013, 17:329-341.
16. Dandona P, Hussain MAM, Varghese Z, Politis D, Flynn DM, Hoffbrand AV Insulin resistance and iron overload. Ann Clin Biochem 1983, 20:77-79.
17. Niederau C, Berger M, Stremmel W, et al. Hyperinsulinaemia in non-cirrhotic haemochromatosis: impaired hepatic insulin degradation?. Diabetologia 1984, 26:441-444.
18. Ferrannini E Insulin resistance, iron, and the liver. Lancet 2000, 355:2181-2182.
19. Arosio P, Ingrassia R, Cavadini P Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta 2009, 1790:589-599.
20. Guyader D, Jacquelinet C, Moirand R, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998, 115:929-936.
21. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000, 343:327-331.
22. Kowdley KV, Belt P, Wilson LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012, 55:77-85. for the NASH Clinical Research Network.
23. Donovan A, Brownlie A, Zhou Y, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000, 403:776-781.
24. Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarc'h A, Deugnier Y Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol 2001, 116:263-270.
25. Aigner E, Theurl I, Haufe H, et al. Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. Gastroenterology 2008, 135:680-688.
26. Hernaez R, Yeung E, Clark JM, Kowdley KV, Brancati FL, Kao WH Hemochromatosis gene and nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2011, 55:1079-1085.
27. George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998, 114:311-318.
28. Fargion S, Mattioli M, Fracanzani AL, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001, 96:2448-2455.
29. Valenti L, Dongiovanni P, Fracanzani AL, et al. Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis 2003, 35:172-178.
30. Younossi ZM, Gramlich T, Bacon BR, et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999, 30:847-850.
31. Chitturi S, Weltman M, Farrell GC, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002, 36:142-149.
32. Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004, 39:179-187.
33. Equitani F, Fernandez-Real JM, Menichella G, et al. Bloodletting ameliorates insulin sensitivity and secretion in parallel to reducing liver iron in carriers of HFE gene mutations. Diabetes Care 2008, 31:3-8.
34. Wenzel BJ, Stults HB, Mayer J Hypoferraemia in obese adolescents. Lancet 1962, 2:327-328.
35. Cheng HL, Bryant C, Cook R, O'Connor H, Rooney K, Steinbeck K The relationship between obesity and hypoferraemia in adults: a systematic review. Obes Rev 2012, 13:150-161.
36. Iwasaki T, Nakajima A, Yoneda M, et al. Serum ferritin is associated with visceral fat area and subcutaneous fat area. Diabetes Care 2005, 28:2486-2491.
37. Dongiovanni P, Ruscica M, Rametta R, et al. Dietary iron overload induces visceral adipose tissue insulin resistance. Am J Pathol 2013, 182:2254-2263.
38. Wlazlo N, van Greevenbroek MM, Ferreira I, et al. Iron metabolism is associated with adipocyte insulin resistance and plasma adiponectin: the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study. Diabetes Care 2013, 36:309-315.
39. Festa M, Ricciardelli G, Mele G, Pietropaolo C, Ruffo A, Colonna A Overexpression of H ferritin and up-regulation of iron regulatory protein genes during differentiation of 3T3-L1 pre-adipocytes. J Biol Chem 2000, 275:36708-36712.
40. Farahani P, Chiu S, Bowlus CL, et al. Obesity in BSB mice is correlated with expression of genes for iron homeostasis and leptin. Obes Res 2004, 12:191-204.
41. Moreno-Navarrete JM, Novelle MG, Catalán V, et al. Insulin resistance modulates iron-related proteins in adipose tissue. Diabetes Care (in press).
42. Tajima S, Ikeda Y, Sawada K, et al. Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice. Am J Physiol Endocrinol Metab 2012, 302:E77-E86.
43. Fernández-Real JM, Moreno JM, Ricart W Circulating retinol-binding protein-4 concentration might reflect insulin resistance-associated iron overload. Diabetes 2008, 57:1918-1925.
44. Moreno-Navarrete JM, Manco M, Ibáñez J, et al. Metabolic endotoxemia and saturated fat contribute to circulating NGAL concentrations in subjects with insulin resistance. Int J Obes (Lond) 2010, 34:240-249.
45. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994, 14:1431-1437.
46. Fernández-Real JM, Moreno JM, Chico B, López-Bermejo A, Ricart W Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance. Diabetes Care 2007, 30:616-621.
47. Gabrielsen JS, Gao Y, Simcox JA, et al. Adipocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest 2012, 122:3529-3540.
48. Schafer AI, Cheron RG, Dluhy R, et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981, 304:319-324.
49. Fernández-Real JM, Izquierdo M, Moreno-Navarrete JM, et al. Circulating soluble transferrin receptor concentration decreases after exercise-induced improvement of insulin sensitivity in obese individuals. Int J Obes (Lond) 2009, 33:768-774.
50. Potashnik R, Kozlovsky N, Ben-Ezra S, Rudich A, Bashan N Regulation of glucose transport and GLUT-1 expression by iron chelators in muscle cells in culture. Am J Physiol 1995, 269:E1052-E1058.
51. Huang J, Simcox J, Mitchell TC, et al. Iron regulates glucose homeostasis in liver and muscle via AMP-activated protein kinase in mice. FASEB J 2013, 27:2845-2854.
52. Adams PC, Deugnier Y, Moirand R, Brissot P The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997, 25:162-166.
53. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002, 359:211-218.
54. Rahier JR, Loozen S, Goebbels RM, Abrahem M The haemochromatotic human pancreas: a quantitative immunohistochemical and ultrastructural study. Diabetologia 1987, 30:5-12.
55. Fernández-Real JM, Peñarroja G, Castro A, García-Bragado F, Hernández-Aguado I, Ricart W Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and β-cell function. Diabetes 2002, 51:1000-1004.
56. Koch RO, Zoller H, Theuri I, et al. Distribution of DMT 1 within the human glandular system. Histol Histopathol 2003, 18:1095-1101.
57. Hudson DM, Curtis SB, Smith VC, et al. Human hephaestin expression is not limited to enterocytes of the gastrointestinal tract but is also found in the antrum, the enteric nervous system, and pancreatic β-cells. Am J Physiol Gastrointest Liver Physiol 2010, 298:G425-G432.
58. MacDonald MJ, Cook JD, Epstein ML, Flowers CH Large amount of (apo)ferritin in the pancreatic insulin cell and its stimulation by glucose. FASEB J 1994, 8:777-781.
59. Fernández-Real JM, Ricart-Engel W, Arroyo E, et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998, 21:62-68.
60. Fernández-Real JM, López-Bermejo A, Ricart W Cross-talk between iron metabolism and diabetes. Diabetes 2002, 51:2348-2354.
61. Vari IS, Balkau B, Kettaneh A, et al. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2007, 30:1795-1801. for the DESIR Study Group.
62. Park SK, Ryoo JH, Kim MG, Shin JY Association of serum ferritin and the development of metabolic syndrome in middle-aged Korean men: a 5-year follow-up study. Diabetes Care 2012, 35:2521-2526.
63. Haap M, Machann J, von Friedeburg C, et al. Insulin sensitivity and liver fat: role of iron load. J Clin Endocrinol Metab 2011, 96:E958-E961.
64. Zheng X, Jiang T, Wu H, et al. Hepatic iron stores are increased as assessed by magnetic resonance imaging in a Chinese population with altered glucose homeostasis. Am J Clin Nutr 2011, 94:1012-1019.
65. Salonen JT, Tuomainen TP, Nyyssönen K, Lakka HM, Punnonen K Relation between iron stores and non-insulin dependent diabetes in men: case-control study. BMJ 1998, 317:727.
66. Swaminathan S, Fonseca VA, Alam MG, Shah SV The role of iron in diabetes and its complications. Diabetes Care 2007, 30:1926-1933.
67. Rajpathak SN, Crandall JP, Wylie-Rosett J, Kabat GC, Rohan TE, Hu FB The role of iron in type 2 diabetes in humans. Biochim Biophys Acta 2009, 1790:671-681.
68. Bao W, Rong Y, Rong S, Liu L Dietary iron intake, body iron stores, and the risk of type 2 diabetes: a systematic review and meta-analysis. BMC Med 2012, 10:119.
69. Zhao Z, Li S, Liu G, et al. Body iron stores and heme-iron intake in relation to risk of type 2 diabetes: a systematic review and meta-analysis. PLoS One 2012, 7:e41641.
70. Kunutsor SK, Apekey TA, Walley J, Kain K Ferritin levels and risk of type 2 diabetes mellitus: an updated systematic review and meta-analysis of prospective evidence. Diabetes Metab Res Rev 2013, 29:308-318.
71. Fleming DJ, Jacques PF, Tucker KL, et al. Iron status of the free-living, elderly Framingham Heart Study cohort: an iron-replete population with a high prevalence of elevated iron stores. Am J Clin Nutr 2001, 73:638-646.
72. Gan W, Guan Y, Wu Q, et al. Association of TMPRSS6 polymorphisms with ferritin, hemoglobin, and type 2 diabetes risk in a Chinese Han population. Am J Clin Nutr 2012, 95:626-632.
73. Fernández-Real JM, Mercader JM, Ortega FJ, Moreno-Navarrete JM, López-Romero P, Ricart W Transferrin receptor-1 gene polymorphisms are associated with type 2 diabetes. Eur J Clin Invest 2010, 40:600-607.
74. Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Sanchón R, San Millán JL, Escobar-Morreale HF Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care 2007, 30:2309-2313.
75. Ciudin A, Hernández C, Simó R Iron overload in diabetic retinopathy: a cause or a consequence of impaired mechanisms?. Exp Diabetes Res 2010, 2010:714108.
76. Yefimova MG, Jeanny JC, Guillonneau X, et al. Iron, ferritin, transferrin, and transferrin receptor in the adult rat retina. Invest Ophthalmol Vis Sci 2000, 41:2343-2351.
77. Konerirajapuram NS, Coral K, Punitham R, Sharma T, Kasinathan N, Sivaramakrishnan R Trace elements iron, copper and zinc in vitreous of patients with various vitreoretinal diseases. Indian J Ophthalmol 2004, 52:145-148.
78. Loebstein R, Lehotay DC, Luo X, Bartfay W, Tyler B, Sher GD Diabetic nephropathy in hypertransfused patients with β-thalassemia: the role of oxidative stress. Diabetes Care 1998, 21:1306-1309.
79. Nankivell BJ, Tay YC, Boadle RA, Harris DC Lysosomal iron accumulation in diabetic nephropathy. Ren Fail 1994, 16:367-381.
80. Moczulski DK, Grzeszczak W, Gawlik B Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. Diabetes Care 2001, 24:1187-1191.
81. Ikeda Y, Enomoto H, Tajima S, et al. Dietary iron restriction inhibits progression of diabetic nephropathy in db/db mice. Am J Physiol Renal Physiol 2013, 304:F1028-F1036.
82. Facchini FS, Saylor KL A low-iron-available, polyphenol-enriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy. Diabetes 2003, 52:1204-1209.
83. Rajapurkar MM, Hegde U, Bhattacharya A, Alam MG, Shah SV Effect of deferiprone, an oral iron chelator, in diabetic and non-diabetic glomerular disease. Toxicol Mech Methods 2013, 23:5-10.
84. Schröder N, Figueiredo LS, de Lima MN Role of brain iron accumulation in cognitive dysfunction: evidence from animal models and human studies. J Alzheimers Dis 2013, 34:797-812.
85. Strachan MW, Reynolds RM, Marioni RE, Price JF Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol 2011, 7:108-114.
86. Morris JK, Bomhoff GL, Gorres BK, et al. Insulin resistance impairs nigrostriatal dopamine function. Exp Neurol 2011, 231:171-180.
87. Wouthuis SF, van Deursen CT, te Lintelo MP, Rozeman CA, Beekman R Neuromuscular manifestations in hereditary haemochromatosis. J Neurol 2010, 257:1465-1472.
88. Cameron NE, Cotter MA Effects of an extracellular metal chelator on neurovascular function in diabetic rats. Diabetologia 2001, 44:621-628.
89. Sullivan JL Stored iron and vascular reactivity. Arterioscler Thromb Vasc Biol 2005, 25:1532-1535.
90. de Valk B, Marx JJ Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med 1999, 159:1542-1548.
91. Yuan XM, Li W Iron involvement in multiple signaling pathways of atherosclerosis: a revisited hypothesis. Curr Med Chem 2008, 15:2157-2172.
92. Li JJ, Meng X, Si HP, et al. Hepcidin destabilizes atherosclerotic plaque via overactivating macrophages after erythrophagocytosis. Arterioscler Thromb Vasc Biol 2012, 32:1158-1166.
93. Valenti L, Dongiovanni P, Motta BM, et al. Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol 2011, 31:683-690.
94. Saeed O, Otsuka F, Polavarapu R, et al. Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler Thromb Vasc Biol 2012, 32:299-307.
95. Sung KC, Kang SM, Cho EJ, Park JB, Wild SH, Byrne CD Ferritin is independently associated with the presence of coronary artery calcium in 12 033 men. Arterioscler Thromb Vasc Biol 2012, 32:2525-2530.
96. Beaton MD, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams P Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013, 37:720-729.
97. Facchini FS, Hua NW, Stoohs RA Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002, 122:931-939.
98. Fernández-Real JM, Peñarroja G, Castro A, García-Bragado F, López-Bermejo A, Ricart W Blood letting in high-ferritin type 2 diabetes: effects on vascular reactivity. Diabetes Care 2002, 25:2249-2255.
99. Houschyar KS, Lüdtke R, Dobos GJ, et al. Effects of phlebotomy-induced reduction of body iron stores on metabolic syndrome: results from a randomized clinical trial. BMC Med 2012, 10:54.
100. Piperno A, Vergani A, Salvioni A, et al. Effects of venesections and restricted diet in patients with the insulin-resistance hepatic iron overload syndrome. Liver Int 2004, 24:471-476.
101. Valenti L, Fracanzani AL, Dongiovanni P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007, 102:1251-1258.
102. Valenti L, Moscatiello S, Vanni E, et al. Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling-a propensity score-adjusted observational study. QJM 2011, 104:141-149.
103. Zacharski LR, Chow BK, Howes PS, et al. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA 2007, 297:603-610.
104. Manco M, Fernandez-Real JM Back to past leeches: repeated phlebotomies and cardiovascular risk. BMC Med 2012, 10:53.
105. Jiang R, Ma J, Ascherio A, Stampfer MJ, Willett WC, Hu FB Dietary iron intake and blood donations in relation to risk of type 2 diabetes in men: a prospective cohort study. Am J Clin Nutr 2004, 79:70-75.
106. Fernández-Real JM, López-Bermejo A, Ricart W Iron stores, blood donation, and insulin sensitivity and secretion. Clin Chem 2005, 51:1201-1205.
107. Valenti L, Fracanzani AL, Fargion S Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance. Gastroenterology 2003, 124:866.
108. Sumida Y, Kanemasa K, Fukumoto K, et al. Effect of iron reduction by phlebotomy in Japanese patients with nonalcoholic steatohepatitis: a pilot study. Hepatol Res 2006, 36:315-321.
109. Shah SV, Fonseca VA Iron and diabetes revisited. Diabetes Care 2011, 34:1676-1677.
110. Mann N Dietary lean red meat and human evolution. Eur J Nutr 2000, 39:71-79.
111. Martínez-González MA, de la Fuente-Arrillaga C, Nunez-Cordoba JM, et al. Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study. BMJ 2008, 336:1348-1351.
112. Mediterranean diet and type 2 diabetes risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study: the InterAct project. Diabetes Care 2011, 34:1913-1918. The InterAct Consortium.
113. Mascitelli L, Goldstein MR Mediterranean diet, lower body iron stores and metabolic syndrome. Int J Clin Pract 2011, 65:1110.
114. MedinePlus Ferritin, (accessed June 20, 2013). http://www.nlm.nih.gov/medlineplus/ency/article/003490.htm.
115. Fernández-Real JM, Pickup JC Innate immunity, insulin resistance and type 2 diabetes. Diabetologia 2012, 55:273-278.